Quick Answer
Twist Bioscience Corp reported Research And Development Expense of $80.29 million for the year ending 2025.
- Twist Bioscience Corp showed a decrease of -11.6% in Research And Development Expense from 2024 to 2025.
- This data is from Twist Bioscience Corp's annual report (Form 10-K), filed with the SEC on November 17, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $4.30 million | Q1 2018: $4.71 million | Q2 2018: $5.27 million | Q4 2018: $7.27 million | Q1 2019: $8.91 million | Q2 2019: $9.01 million | Q4 2019: $10.30 million | Q1 2020: $10.63 million | Q2 2020: $10.44 million | Q4 2020: $14.00 million | Q1 2021: $15.79 million | Q2 2021: $19.84 million | Q4 2021: $22.63 million | Q1 2022: $31.23 million | Q2 2022: $36.84 million | Q4 2022: $31.24 million | Q1 2023: $27.38 million | Q2 2023: $24.53 million | Q4 2023: $23.10 million | Q1 2024: $24.15 million | Q2 2024: $22.47 million | Q4 2024: $21.31 million | Q1 2025: $23.92 million | Q2 2025: $18.05 million | Q4 2025: $17.13 million.
- Over the full 9 years of available data (2017 to 2025), Twist Bioscience Corp's Research And Development Expense has grown by 318.8%.
- Historical annual values: Fiscal year 2025: $80.29 million | Fiscal year 2024: $90.85 million | Fiscal year 2023: $106.89 million | Fiscal year 2022: $120.31 million | Fiscal year 2021: $69.07 million | Fiscal year 2020: $43.01 million | Fiscal year 2019: $35.68 million | Fiscal year 2018: $20.35 million | Fiscal year 2017: $19.17 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: